Elanco Animal Health
$ 24.17
0.50%
12 Jun - close price
- Market Cap 12,011,762,000 USD
- Current Price $ 24.17
- High / Low $ 24.41 / 24.00
- Stock P/E N/A
- Book Value 13.02
- EPS -0.50
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.04 %
- 52 Week High 27.72
- 52 Week Low 13.16
About
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana.
Analyst Target Price
$29.79
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-24 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-26 | 2023-11-07 | 2023-08-07 |
| Reported EPS | 0.4 | 0.13 | 0.19 | 0.26 | 0.37 | 0.14 | 0.13 | 0.3 | 0.34 | 0.08 | 0.18 | 0.18 |
| Estimated EPS | 0.34 | 0.1135 | 0.13 | 0.2 | 0.3 | 0.1486 | 0.12 | 0.24 | 0.27 | 0.11 | 0.12 | 0.05 |
| Surprise | 0.06 | 0.0165 | 0.06 | 0.06 | 0.07 | -0.0086 | 0.01 | 0.06 | 0.07 | -0.03 | 0.06 | 0.13 |
| Surprise Percentage | 17.6471% | 14.5374% | 46.1538% | 30% | 23.3333% | -5.7873% | 8.3333% | 25% | 25.9259% | -27.2727% | 50% | 260% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELAN
2026-06-10 07:39:49
Brandes Investment Partners LP reduced its stake in Elanco Animal Health (NYSE:ELAN) by 29.3% in the fourth quarter but still holds 4.2 million shares valued at $95.09 million. Elanco reported strong quarterly results, beating EPS and revenue expectations, and analysts maintain a "Moderate Buy" rating with a consensus price target of $28.20. Insider buying also occurred in May, indicating confidence in the company.
2026-06-09 23:10:36
Elanco Animal Health Inc (ELAN) shares rose 3.5% to $24.50 on June 9, 2026, but are considered 57.7% overvalued according to GuruFocus's GF Value™ estimate of $15.54. Despite a strong momentum score (10/10) within its GF Score™ of 67/100, the company shows concerns in financial strength (5/10) and valuation (3/10). Insider activity reveals $0.2 million in purchases over the last three months with no selling, suggesting insider confidence despite the overvaluation.
2026-06-09 09:09:56
Norges Bank has initiated a new position in Elanco Animal Health (NYSE:ELAN), acquiring 1.43 million shares valued at about $32.42 million. This investment highlights increasing institutional interest in Elanco, which recently reported strong quarterly results and holds a "Moderate Buy" consensus rating from analysts.
2026-06-08 08:39:50
Clearbridge Investments LLC slightly reduced its stake in Elanco Animal Health by 3.8% in Q4, but still holds 5.67 million shares valued at $128.4 million. Institutional ownership of ELAN stands at 97.48%. The company recently reported Q1 EPS of $0.40 and revenue of $1.37 billion, exceeding expectations, and analysts maintain a "Moderate Buy" rating with a target price of $28.20.
2026-06-07 13:39:50
Harvest Fund Management Co. Ltd significantly reduced its stake in Elanco Animal Health Incorporated ($ELAN) by 72.7% in Q4, holding 16,183 shares valued at $366,000. Despite this, institutional ownership of ELAN remains high at 97.48%, with other institutional investors adjusting their positions. Elanco recently reported stronger-than-expected quarterly results, and analysts maintain a "Moderate Buy" rating for the stock.
2026-06-07 13:39:50
TD Asset Management Inc. significantly increased its stake in Elanco Animal Health (NYSE:ELAN) by 47.6% in the fourth quarter, purchasing an additional 516,628 shares and bringing its total holdings to over 1.6 million shares valued at approximately $36.3 million. This increase comes as Elanco reported better-than-expected first-quarter earnings, with EPS of $0.40 against an estimated $0.34 and revenue exceeding forecasts at $1.37 billion. Insiders, including CEO Jeffrey N. Simmons and Rajeev A. Modi, have also recently bought shares, reinforcing a "Moderate Buy" consensus among Wall Street analysts with an average target price of $28.20.
